Description
Toll-like receptors (TLRs) are a family of highly conserved germlineencoded pattern-recognition receptors that are essential for host immune responses. TLR ligands represent a promising class of immunotherapeutics or vaccine adjuvants with the potential to generate an effective antitumor immune response. The TLR7/8 agonists have aroused interest because they not only activate antigen-presenting cells but also promote activation of T and natural killer (NK) cells. Recognition of TLR7 ligands by TLR7 leads to the overall activation and maturation of antigen-presenting cells, such as dendritic cells (DCs), and the secretion of proinflammatory cytokines and type I IFN. After recognition of TLR7 ligand, mature DCs are able to fully activate effector T cells and drive more potent immune responses
Resiquimod, a chemical analog of imiquimod, is a potent modulator of the immune response. Specifically, it was demonstrated that resiquimod activates the innate immune system via TLR-7 through the activation of the MyD88 pathway in antigen presenting cells, including dendritic cells.
Formula: C17H22N4O2
Purity: ≥98%
Solubility: Soluble to 100 mM in DMSO and to 50 mM in ethanol
Loading ......
